Despite industry outcry, new data question how relevant the rule would have been anyway.
What goes down must come up.
US approvals of high-risk medical devices are way down.
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
Abbott’s latest aortic valve launch is unlikely to gain it a meaningful slice of the market; meanwhile, Edwards’ attention has switched to tricuspid.
But does it hit hard enough?